Treatment of ANCA-associated vasculitides (AAV)

Julia U. Holle*, Wolfgang L. Gross

*Corresponding author for this work
36 Citations (Scopus)


Treatment of AAV follows the principle of a combined remission induction and maintenance strategy and is adapted in a stage and activity-adapted fashion. So far the combination therapy of glucocorticoids and conventional immunosuppressive drugs has mainly been used to control disease. This approach has led to a significant improvement in outcome in spite of persistently high early mortality rates of nearly 11% within the first year. Besides conventional treatment, biologics have emerged as a new treatment option. The paper summarizes the current evidence for the use of conventional therapy and biologics in AAV.

Original languageEnglish
JournalAutoimmunity Reviews
Issue number4
Pages (from-to)483-486
Number of pages4
Publication statusPublished - 2013

Research Areas and Centers

  • Academic Focus: Center for Infection and Inflammation Research (ZIEL)


Dive into the research topics of 'Treatment of ANCA-associated vasculitides (AAV)'. Together they form a unique fingerprint.

Cite this